ASO functioning towards personalized medicine.

Global circuit of ribosome synthesis.

METTL16 is an N6-methyladenosine RNA methyltransferase with a variety of targets including the U6 small nuclear RNA, the MALAT1 long noncoding RNA, and the MAT2A messenger RNA. The role of METTL16 in the cell is still being explored as are the functions and importance of its various domains (RBD, N terminal RNA binding domain; VCR, vertebrate conserved region).

Nonsense suppressor tRNAs display promise as therapeutic agents for suppressing premature termination codons, and alleviating disease through seamless rescue of full-length protein and stabilized mRNA.

Identification of RNA methyltransferases is a major driving force in the field of epitranscriptomics.

A development of the methods used to study the length and composition of poly(A) tails, uncovering the 3′-end tailing as a much more complex and impactful process than previously thought.

microRNAs are short noncoding regulatory RNAs with important roles in cancer biology. microRNAs are informative biomarkers for early cancer detection and treatment decisions. microRNAs are being evaluated in clinical trials as new drugs for personalized cancer medicine.

Alternative splicing potentially leads to impacts on protein production and function. Multiple experimental and computational approaches have been proposed to measure how alternative splicing reshapes the proteome.

Cap-independenttranslation of circular RNAs into proteins using the internal ribosomal entrysites and N6-methyladenosine modifications.